✦ LIBER ✦

Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer

✍ Scribed by Thomas J. Herzog; Matthew A. Powell; Janet S. Rader; Randall Gibb; David G. Mutch

Book ID: 113960625
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 127 KB
Volume: 103
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2006.04.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II evaluation of topotecan and nav

Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer

✍ Thomas J. Herzog; Matthew A. Powell; Janet S. Rader; Randall K. Gibb; Lynne Lipp 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 424 KB

Phase II Evaluation of 3-Day Topotecan w

Phase II Evaluation of 3-Day Topotecan with Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer

✍ Parviz Hanjani; Susan Nolte; Mark S. Shahin 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Phase II study of weekly topotecan in pa

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

✍ Tally Levy; Moshe Inbar; Joseph Menczer; Dan Grisaru; Marek Glezerman; Tamar Saf 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 140 KB

A phase II trial of pemetrexed in combin

A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer

✍ Jalid Sehouli; Ana Maria Alvarez; Shokoufeh Manouchehrpour; Prafull Ghatage; Cez 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Role of salvage chemotherapy with topote

Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study

✍ Ghamande, Sharad A.; Piver, M. Steven 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

## Background and Objectives: We assessed the role of salvage chemotherapy with topotecan and cisplatin in patients with platinum-and paclitaxel-resistant advanced and recurrent ovarian or primary peritoneal cancer, based on the reported in vivo and in vitro synergism between these two drugs. Meth

CA-125 response in patients with recurre

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan

✍ Gabrielle Gossner; Robert L. Coleman; David G. Mutch; Neil S. Horowitz; Janet S. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 270 KB